Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol-Myers Squibb (BMY) has secured a global exclusive license for Agenus' bispecific antibody AGEN1777, targeting TIGIT. The deal entails a $200 million upfront payment and additional potential milestones totaling up to $1.36 billion, plus royalties on sales. AGEN1777, designed to enhance anti-tumor activities, is currently in late preclinical development, with an IND application expected in Q2 2021. Bristol-Myers Squibb aims to advance AGEN1777 for high-priority tumor indications like non-small cell lung cancer, highlighting its commitment to immuno-oncology.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 25, 2021. The session will feature David Elkins, CFO, and Samit Hirawat, Chief Medical Officer, answering questions about the company at 1 p.m. ET. Investors and the public can listen to the live webcast at investor.bms.com, and an archived version will be available later the same day.
Bristol Myers Squibb, a global biopharmaceutical company, focuses on developing innovative medicines for serious diseases.
Bristol Myers Squibb (BMY) reported results from the Phase 3 EXPLORER-HCM study of mavacamten, a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM), presented at ACC.21. After 30 weeks, patients treated with mavacamten experienced a significant improvement in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) compared to placebo, with a mean difference of 9.1 points (p<0.001). A total of 36% of mavacamten patients achieved a clinically meaningful improvement (≥20 points) versus 15% in the placebo group. Results indicate significant potential for mavacamten in enhancing patient health status.
Bristol Myers Squibb (NYSE: BMY) presented significant research at the 2021 ASCO and EHA meetings, showcasing its commitment to addressing unmet needs in cancer and blood disorders. Findings from over 75 studies across 18 cancer types were highlighted, including durable survival benefits from Opdivo (nivolumab) and synergistic effects with Yervoy (ipilimumab). Key presentations featured the RELATIVITY-047 trial and CheckMate studies, indicating advancements in therapeutic combinations and cell therapies aimed at improving patient outcomes.
DarwinHealth has announced a collaboration with Bristol-Myers Squibb (BMY) for the Novel Cancer Target Initiative (NCTI). This initiative utilizes advanced quantitative systems biology to discover novel cancer targets across various tumor types. DarwinHealth will provide proprietary drug database insights to identify high-value cancer targets, which could lead to new anti-cancer therapies. The collaboration also builds on a previous partnership established in 2019 and includes upfront and milestone payments for DarwinHealth.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the 2021 Bank of America Securities Virtual Health Care Conference on May 11, 2021. Chris Boerner, Ph.D., Executive Vice President and Chief Commercialization Officer, will lead the discussion at 5 p.m. ET, addressing company matters. Investors and the public can listen via a live webcast at investor.bms.com. An archived version will be available the same day. This event provides an opportunity for stakeholders to gain insights into Bristol Myers Squibb's ongoing initiatives and market strategies.
Bristol Myers Squibb (NYSE: BMY) announced the presentation of data regarding mavacamten at the American College of Cardiology’s 70th Annual Scientific Session from May 15-17, 2021. Key presentations include a late-breaking oral presentation on the EXPLORER-HCM Phase 3 trial results demonstrating health status improvements in patients with obstructive hypertrophic cardiomyopathy (oHCM). Interim results from the MAVA-LTE study indicate mavacamten is well tolerated, showing lasting benefits in various cardiac metrics. The potential first-in-class treatment aims to address unmet medical needs in oHCM patients.
Bristol Myers Squibb (NYSE: BMY) announced that the FDA has accepted its supplemental Biologics License Application for Opdivo (nivolumab) aimed at treating high-risk muscle-invasive urothelial carcinoma post-surgery. The application received Priority Review status, with a PDUFA goal date of September 3, 2021. This follows positive results from the CheckMate -274 trial demonstrating significant disease-free survival improvements. Opdivo is recognized for its potential to provide a critical adjuvant immunotherapy option for patients facing high recurrence risk.
Bristol Myers Squibb (NYSE:BMY) reported Q1 2021 revenues of $11.1 billion, up 3% year-over-year, with an 8% increase excluding COVID-19 buying patterns. Net earnings were $2.0 billion or $0.89 per share, compared to a loss of $775 million in Q1 2020. The company raised its GAAP EPS guidance to $3.18-$3.38 and affirmed non-GAAP EPS guidance of $7.35-$7.55. Key product highlights include growth in Eliquis and Yervoy, while Opdivo saw a 3% decline. Regulatory progress was noted for several drugs, enhancing future growth opportunities.
Bristol Myers Squibb (NYSE: BMY) will participate in the 7th Annual Virtual Truist Life Sciences Summit on May 5, 2021. Senior executives Adam Lenkowsky and Winselow Tucker will discuss the company's oncology and hematology sectors during a live webcast at 8 a.m. ET. Interested investors and the public can access the session through the company’s investor website. An archived version will be available later that day.